A Harm-Reduction–Oriented Clinical Framework for Ibogaine Administration and Risk Management
Mark Picard
October 3, 2026 preprint DOI: 10.31219/osf.io/b67ts_v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Intervention | Ibogaine |
| Topics | Ibogaine |
| Key points | Argues that serious adverse events from ibogaine administration arise largely from preventable factors in patient selection, preparation, dosing, monitoring, and post-treatment care, and proposes a harm-reduction clinical framework emphasizing dynamic risk assessment, cardiac electrophysiology, metabolic variability, and cumulative risk interactions over fixed protocol adherence. |
Abstract
Ibogaine is a psychoactive indole alkaloid with reported potential to interrupt opioid withdrawal and reduce substance use. Despite increasing interest in its therapeutic applications, ibogaine administration remains associated with significant risk, particularly related to cardiac conduction abnormalities and autonomic instability. Most serious adverse events appear to arise from identifiable and potentially preventable factors involving patient selection, preparation, dosing, monitoring, and post-treatment care. In addition to physiological risk, inadequate psychological containment, screening, and long-term post-treatment support may contribute to destabilization, behavioral dysregulation, or harm in vulnerable populations. This paper presents a conceptual, harm-reduction–oriented clinical framework for ibogaine administration and risk management. The model integrates existing literature, physiological principles, and observational practices into a structured approach emphasizing dynamic risk assessment rather than fixed protocol adherence.Key domains include patient selection and stratification, clinical screening, pre-treatment stabilization, adaptive dosing strategies, continuous monitoring, and post-treatment integration. Particular emphasis is placed on cardiac electrophysiology, metabolic variability, and cumulative risk interactions.This framework is intended to support safer decision-making in real-world contexts where ibogaine is currently used and to provide a foundation for future clinical research and protocol development.
Comparable studies
Other theoretical and historical papers on ibogaine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Biosynthesis of an Anti-Addiction Agent from the Iboga Plant. | 2019 | Theoretical or philosophical paper | |
| Bioinspired Collective Syntheses of Iboga-Type Indole Alkaloids. | 2016 | Theoretical or philosophical paper | |
| Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Humans | 2006 | Theoretical or philosophical paper | |
| Iboga Alkaloids. II.1 the Structures of Ibogaine, Ibogamine and Tabernanthine | 1957 | Theoretical or philosophical paper | |
| Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes. | 2003 | Theoretical or philosophical paper |